EUVIMEDEUVIMED entdecken
Netzwerk-Metaanalyse

Effect of Induction Therapy Dose on Survival in Abo-Incompatible Kidney Transplantation: A Network Meta-Analysis Using Recent Data

Jin Ho Lee, Hee Ryong Lee, Seoung Woo Lee, Joon Ho Song, Seun Deuk Hwang

Transplantation Proceedings · 2024

DOI: 10.1016/j.transproceed.2024.01.026 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Jin Ho Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Leesin Hemodialysis and Intervention Clinic, Busan, Korea. Hauptthemen laut MEDLINE: Kidney Transplantation, ABO Blood-Group System, Rituximab, Blood Group Incompatibility. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Ministry of Science, ICT and Future Planning, National Research Foundation of Korea, Inha University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rituximab is an essential induction immunosuppressant for ABO-incompatible kidney transplantation (KT) (ABOi-KT). However, studies on the optimal dose of rituximab are insufficient, and there are dosage differences between transplant centers and countries. Therefore, we conducted a study to determine the survival outcomes of patients receiving the most effective and safe dose of rituximab during ABOi-KT. METHODS: Studies on rituximab dose were divided into four groups: ABO compatible, 1) placebo, 2) rituximab 200 mg, 3) rituximab 200-500 mg, and 4) rituximab 500 mg. We searched the CENTRAL, MEDLINE, EMBASE, and Science Citation Index Expanded databases from 1970 to February 2022.9 . The inclusion criteria were adult patients (>18 years old). Reviews, observational studies, and clinical trials that did not clearly define outcomes or that did not have graft failure as an outcome were excluded. We performed direct and indirect network meta-analyses using Bayesian models and ranked different rituximab doses using a generation mixed treatment comparison (GeMTC) and Stata version 13. The NMA approach was evaluated using the GRADE framework, which specifies four levels of certainty for a given result: high, moderate, low, and very low. The outcomes included patient survival, graft failure, and bacterial and viral infections. RESULTS: Twenty-five trials, including 5,378 subjects, were divided into the following four groups: 1) placebo, 2) rituximab 200 mg, 3) rituximab 200-500 mg, and 4) rituximab 500 mg. We focused on survival outcomes according to the dose of rituximab when patients received induction therapy for ABOi-KT. The mortality rate was significantly lower in the ABO-compatible and rituximab 200 mg groups (odds ratio [OR] 0.27, 95% CrI: 0.071-0.91 and OR 0.14, 95% CrI 0.036-0.47), compared with that in the placebo group. CONCLUSIONS: We found that low-dose rituximab in ABO-i KT was effective compared to the high-dose and placebo in maintaining the survival rate. However, large-scale and long-term data are necessary for further validation of our findings. Additionally, the use of smaller doses of rituximab will require further discussion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationABO Blood-Group SystemRituximabBlood Group IncompatibilityImmunosuppressive AgentsGraft SurvivalHumansGraft Rejection

Substanzen

ABO Blood-Group SystemRituximabImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Leesin Hemodialysis and Intervention Clinic, Busan, Korea.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea. Electronic address: sdhwang0902@inha.ac.kr.

Förderung

  • Ministry of Science, ICT and Future Planning
  • National Research Foundation of Korea
  • Inha University

Zitieren

APA

Lee, J. H., Lee, H. R., Lee, S. W., Song, J. H., & Hwang, S. D. (2024). Effect of Induction Therapy Dose on Survival in Abo-Incompatible Kidney Transplantation: A Network Meta-Analysis Using Recent Data. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.01.026

Vancouver

Lee JH, Lee HR, Lee SW, Song JH, Hwang SD. Effect of Induction Therapy Dose on Survival in Abo-Incompatible Kidney Transplantation: A Network Meta-Analysis Using Recent Data. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.01.026

BibTeX
@article{Lee2024,
  author = {Lee, Jin Ho and Lee, Hee Ryong and Lee, Seoung Woo and Song, Joon Ho and Hwang, Seun Deuk},
  title = {Effect of Induction Therapy Dose on Survival in Abo-Incompatible Kidney Transplantation: A Network Meta-Analysis Using Recent Data},
  journal = {Transplantation Proceedings},
  year = {2024},
  doi = {10.1016/j.transproceed.2024.01.026}
}
Kostenlos starten →